GlassScriptPhysician profile
Steven M Laporte
NPI 1952793622
$11,095.66
in general payments reported to CMS, 2019-2025
26 companies · $4,258 in 2025
The $4,258 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $336 · 2022: $801 · 2023: $1,458 · 2024: $4,241 · 2025: $4,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,840 · Consulting Fee: $1,680 · Travel and Lodging: $1,264 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,840.36 |
| Consulting Fee | $1,680.00 |
| Travel and Lodging | $1,264.17 |
| Education | $173.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $2,530.60 | 2022-2025 | Tyvaso, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $2,315.34 | 2021-2025 | Breztri, Airsupra, Tezspire |
| Inspire Medical Systems, INC. | $1,523.07 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $1,434.11 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $531.41 | 2021-2025 | Dupixent |
| Amgen INC. | $419.15 | 2024-2025 | Tezspire |
| Verona Pharma, INC. | $335.96 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.76 | 2022-2025 | Ofev |
| Genzyme Corporation | $217.56 | 2022-2025 | |
| Philips North America LLC | $183.31 | 2025 | Incourage Airway Clearance Therapy, Respiratory, Vest Therapy Und |
| Janssen Pharmaceuticals, INC | $179.74 | 2021 | |
| Grifols USA, LLC | $173.91 | 2022-2025 | Prolastin-C Liquid |
| Insmed, INC. | $156.16 | 2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $143.43 | 2022-2025 | |
| Pulmonx Corporation | $127.85 | 2024-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $102.58 | 2024-2025 | |
| Electromed, INC. | $85.51 | 2025 | Smartvest |
| Novo Nordisk INC | $83.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $60.57 | 2025 | |
| Tactile Systems Technology INC | $47.23 | 2024 | Flexitouch Plus, Entre Plus |
| Actelion Pharmaceuticals US, INC. | $47.15 | 2024 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $45.90 | 2025 | Glassia |
| Lilly USA, LLC | $22.80 | 2025 | Zepbound |
| Zoll Respicardia, INC. | $22.37 | 2023 | Remede System |
| Vifor Pharma, INC. | $16.01 | 2024 | Zemaira |
| Ani Pharmaceuticals, INC. | $15.54 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Laporte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.